Clinical study reports E2086's potential to promote wakefulness in narcolepsy type-1, suggesting a new treatment option.
To report results from the first clinical study of E2086, a novel, selective orexin receptor-2 (OX2R) agonist, in patients with narcolepsy type-1 (NT1).
No takes yet. Share an insight, caveat, or question.
Corser et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: